Extending Dosing Interval May Not Impact Safety, Efficacy of ICIs in Lung Cancer
Survival outcomes were similar for patients with an extended dosing interval and patients who received standard dosing.
Non-Small Cell Lung Cancer
Stage Shift Tied to Decreased Population Mortality in NSCLC
A stage shift from later- to earlier-stage disease during the last decade was associated with improved survival among patients with NSCLC.
Patritumab Deruxtecan Gets Breakthrough Tx Status for Metastatic EGFR-Mutated NSCLC
Patritumab deruxtecan consists of a fully human anti-HER3 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker.
First-Line Osimertinib: Proceed With Caution in Elderly Patients With NSCLC
The high frequency of pneumonitis “is a serious concern,” according to researchers.
Physical Manipulation Pulmonary Rehabilitation Improved Lung Function After Lobectomy for NSCLC
A randomized, controlled trial was conducted to determine if physical pulmonary rehabilitation could improve outcomes after lobectomy for patients with NSCLC.
ctDNA Analysis Can Predict Recurrence and Guide Treatment in NSCLC
ctDNA positivity was associated with worse recurrence-free survival.
Adding Chemo to Immunotherapy Improves PFS, Not OS, in Non-Small Cell Lung Cancer
The 1-year overall survival rate was 59% with chemotherapy plus immunotherapy and 55% with immunotherapy alone.
EGFR Positivity May Be Poor Predictor of Recurrence in Non-Small Cell Lung Cancer
Despite high rates of recurrence, 37% of patients with stage IB-IIIA NSCLC remained disease-free at 5 years.
Proton Pump Inhibitors May Reduce Efficacy of Atezolizumab in Non-Small Cell Lung Cancer
Proton pump inhibitor use was tied to worse overall and progression-free survival.
Adjuvant Gefitinib No Better Than Chemo for NSCLC With EGFR Mutations
Gefitinib did not improve disease-free or overall survival.
- Loading...
Loading...
Next post in Lung Cancer
Loading... 
Loading...